In 2014 Bioarray pioneered the application of next generation sequencing (NGS) for Preimplantation Genetic Diagnosis (PGS & PGD). Bioarray lab integrates informativity testing, monogenic-disease diagnosis and aneuploidy screening (i.e. PGD setup + PGD + PGS) in a single fast robust NGS workflow, providing unparalleled benefits to patients.
For the first time it is possible to use this technology for PGD allowing not only to select those embryos with a higher probability of implantation and thus drastically improve the IVF success rates, but also to use it as a diagnostic tool for couples at higher risk of having children with genetic conditions.
Bioarray performs PGS and PGD with the three kinds of cells typically biopsied by IVF labs: polar bodies, day-3 embryo biopsy (blastomeres) and day-5 blastocyst biopsy (trophoectoderm).
Bioarray launched this new NGS testing after conducting an extensive validation study, based on the comparison of PGS results by NGS to well established aCGH, with more than 100 embryos diagnosed and 100% diagnosis correspondence by both techniques.